Personal profile
Research Strategic Pillar
The Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
Dive into the research topics where Yanping Hu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
- 12 Article
-
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old
Diya, O., Gayed, J., Lowry, F. S., Ma, H., Bangad, V., Mensa, F., Zou, J., Xie, X., Hu, Y., Cutler, M., Belanger, T., Cooper, D., Xu, X., Koury, K., Türeci, Ö., Şahin, U., Swanson, K. A., Modjarrad, K., Anderson, A. S. & Gurtman, A. & 1 others, , Apr 11 2025, In: Vaccine. 52, 126869.Research output: Contribution to journal › Article › peer-review
Open Access4 Link opens in a new tab Scopus citations -
Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3
Hu, Y., Zou, J., Nguyen, M. D., Chang, H. C., Yeung, J., Hao, H., Shi, P. Y., Ren, P. & Xie, X., Jun 2025, In: mBio. 16, 6Research output: Contribution to journal › Article › peer-review
Open Access8 Link opens in a new tab Scopus citations -
Mechanistic insights into dengue virus inhibition by a clinical trial compound NITD-688
Wang, Y., Sun, L., Fernandes, L., Wang, Y. H., Zou, J., Franklin, S. J., Hu, Y., Palmer, L. K., Yeung, J., Barriga, D., Russell, W. K., Moquin, S. A., Shi, P. Y., Skepper, C. & Xie, X., Apr 1 2025, In: Proceedings of the National Academy of Sciences of the United States of America. 122, 13, e2426922122.Research output: Contribution to journal › Article › peer-review
Open Access9 Link opens in a new tab Scopus citations -
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial
Diya, O., Gayed, J., Lowry, F. S., Ma, H., Bangad, V., Mensa, F., Zou, J., Xie, X., Hu, Y., Cutler, M., Belanger, T., Cooper, D., Xu, X., Mogg, R., Türeci, Ö., Şahin, U., Swanson, K. A., Modjarrad, K., Anderson, A. S. & Gurtman, A. & 1 others, , Aug 2025, In: Infectious Diseases and Therapy. 14, 8, p. 1973-1987 15 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial
on behalf of the C4591054 Study Group, Feb 2024, In: Vaccines. 12, 2, 118.Research output: Contribution to journal › Article › peer-review
Open Access31 Link opens in a new tab Scopus citations